PIPE-505 / Contineum Therap - LARVOL DELTA

Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss (clinicaltrials.gov) - P1/2; N=28; Completed; Sponsor: Pipeline Therapeutics, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion • Otorhinolaryngology

Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss (clinicaltrials.gov) - P1/2; N=24; Active, not recruiting; Sponsor: Pipeline Therapeutics, Inc.; Trial completion date: Mar 2021 ➔ Jun 2021; Trial primary completion date: Mar 2021 ➔ Jun 2021

Clinical • Trial completion date • Trial primary completion date • Otorhinolaryngology

Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss (clinicaltrials.gov) - P1/2; N=24; Active, not recruiting; Sponsor: Pipeline Therapeutics, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Otorhinolaryngology

Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss (clinicaltrials.gov) - P1/2; N=24; Recruiting; Sponsor: Pipeline Therapeutics, Inc.; Trial completion date: Jul 2021 ➔ Mar 2021; Trial primary completion date: Nov 2020 ➔ Mar 2021

Clinical • Trial completion date • Trial primary completion date • Otorhinolaryngology

Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss (clinicaltrials.gov) - P1/2; N=24; Recruiting; Sponsor: Pipeline Therapeutics, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open